Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18590378 | 0.95 | KDM4E (0.38) | L3MBTL1POLBMEN1KMT2AALDH2 | |
| SCHEMBL25180363 | 0.84 | MAPT (0.31) | MEN1KMT2AMAPT | |
| SCHEMBL16549482 | 0.80 | ALDH1A1 (0.39) | POLBALDH1A1MCL1CYP2D6PRKAB2 | |
| SCHEMBL8257439 | 0.79 | SLC6A4 (0.42) | ALDH1A1KDM4EHTR1ASLC6A4CYP2D6 | |
| SCHEMBL264987 | 0.78 | ALDH1A1 (0.46) | L3MBTL1POLBMEN1KMT2AMAPT | |
| SCHEMBL29466255 | 0.78 | ALDH1A1 (0.46) | L3MBTL1POLBMEN1KMT2AMAPT | |
| SCHEMBL14478367 | 0.77 | POLB (0.40) | L3MBTL1POLBMEN1KMT2AALDH2 | |
| SCHEMBL282022 | 0.76 | HSD17B10 (0.39) | L3MBTL1POLBKMT2AALDH2MAPT | |
| SCHEMBL23378586 | 0.74 | L3MBTL1 (0.38) | L3MBTL1POLBMEN1KMT2AALDH2 | |
| SCHEMBL14477684 | 0.74 | POLB (0.38) | L3MBTL1POLBMEN1KMT2AALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617228-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160194294-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS | 2016-07-07 | — | — | US | disclosed |
| US-9266845-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150065706-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS | 2015-03-05 | — | — | US | disclosed |
| US-8895553-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895553-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140256732-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256732-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2014-09-11 | — | — | US | disclosed |
| US-8772479-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NOD2, HTT, CUL5 | L3MBTL1 3928/4885POLB 2904/4885MEN1 2396/4885 |
| US-20140256732-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NOD2, HTT, IPO5 | L3MBTL1 3898/4885POLB 1725/4885MEN1 2913/4885 |
| US-20160194294-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NOD2, HTT, IPO5 | L3MBTL1 3898/4885POLB 1725/4885MEN1 2913/4885 |
| US-20150065706-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NOD2, HTT, IPO5 | L3MBTL1 3898/4885POLB 1725/4885MEN1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.